Patient-centric clinical pharmacology advances the path to personalized medicine

Biomarkers in Medicine

Volumn 5, Issue 6, 2011, Pages 697-700

  Waldman, Scott A ^a   Terzic, Andre ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; BIOMEDICINE; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GENETIC VARIABILITY; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HEALTH CARE NEED; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MOLECULAR MECHANICS; MOLECULAR THERAPY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT SAFETY; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; PHENOTYPE;

EID: 82755161134     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.78     Document Type: Review

References (30)

1. Waldman SA, Terzic A. Molecular therapeutics from knowledge to delivery. Clin. Pharmacol. Ther. 87(6), 619-623 (2010).
2. Waldman SA, Terzic A: Translational medicine in the era of health care reform. Clin. Transl. Sci. 2(2), 96-97 (2009).
3. Waldman SA, Kraft WK, Nelson TJ, Terzic A. Clinical pharmacology: a paradigm for individualized medicine. Biomarkers Med. 3(6), 679-684 (2009).
4. Waldman SA, Hohl RJ, Kearns GL, Swan SJ, Terzic A. Clinical pharmacology as a foundation for translational science. Clin. Pharmacol. Ther. 90(1), 10-13 (2011).
5. Waldman SA, Christensen NB, Moore JE, Terzic A. Clinical pharmacology: the science of therapeutics. Clin. Pharmacol. Ther. 81(1), 3-6 (2007). (Pubitemid 46050856)
6. Waldman SA, Terzic A. Molecular therapy drives patient-centric health care paradigms. Clin. Transl. Sci. 3(4), 170-171 (2010).
7. Zhao P, Zhang L, Grillo JA et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89(2), 259-267 (2010).
8. Terzic A, Waldman SA. Translational medicine: path to personalized and public health. Biomarkers Med. 4(6), 787-790 (2010).
9. Giacomini KM, Brett CM, Altman RB et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin. Pharmacol. Ther. 81(3), 328-345 (2007). (Pubitemid 46364488)
10. Lesko LJ. Paving the critical path: how can clinical pharmacology help achieve the vision? Clin. Pharmacol. Ther. 81(2), 170-177 (2007). (Pubitemid 46174813)
11. Mack A, Balogh E, Micheel CM. Perspectives on Biomarker and Surrogate Endpoint Evaluation. National Academies Press, Washington, DC, USA (2011).
12. Waldman SA, Terzic A. Molecular diagnostics. At the nexus of individualized medicine, health care delivery, and public policy. Clin. Transl. Sci. 2(1), 6-8 (2009).
13. Kroetz DL, Yee SW, Giacomini KM. The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin. Pharmacol. Ther. 87(1), 109-116 (2010).
14. Lesko LJ, Zineh I, Huang SM. What is clinical utility and why should we care? Clin. Pharmacol. Ther. 88(6), 729-733 (2010).
15. Terzic A, Waldman S. Chronic diseases: the emerging pandemic. Clin. Transl. Sci. 4(3), 225-226 (2011).
16. Waldman SA, Terzic A. Bionic technologies transforming the science of healthcare delivery. Clin. Transl. Sci. 4(2), 84-86 (2011).
17. Waldman SA, Terzic A. Clinical translational science 2020: disruptive innovation redefines the discovery-application enterprise. Clin. Transl. Sci. 4(1), 69-71 (2011).
18. Waldman SA, Terzic A. Clinical and translational science: from bench-bedside to global village. Clin. Transl. Sci. 3(5), 254-257 (2010).
19. Waldman SA, Kraft WK, Nelson TJ, Terzic A. Experimental therapeutics: a paradigm for personalized medicine. Clin. Transl. Sci. 2(6), 436-438 (2009).
20. Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin. Pharmacol. Ther. 86(5), 475-479 (2009).
21. Huang SM, Zhao H, Lee JI et al. Therapeutic protein-drug interactions and implications for drug development. Clin. Pharmacol. Ther. 87(4), 497-503 (2010).
22. Zhang Y, Zhang L, Abraham S et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin. Pharmacol. Ther. 85(3), 305-311 (2009).
23. Griggs JJ. Personalized medicine: a perk of privilege? Clin. Pharmacol. Ther. 86(1), 21-23 (2009).
24. Waldman SA, Terzic A. Pharmacoeconomics in the era of individualized medicine. Clin. Pharmacol. Ther. 84(2), 179-182 (2008).
25. Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT. Clinically available pharmacogenomics tests. Clin. Pharmacol. Ther. 86(1), 109-113 (2009).
26. Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin. Pharmacol. Ther. 87(6), 652-662 (2010).
27. Terzic A, Perez-Terzic C. Channelopathies: decoding disease pathogenesis. Sci. Transl. Med. 2(42), 42ps37 (2010).
28. Nelson TJ, Martinez-Fernandez A, Terzic A. Induced pluripotent stem cells: developmental biology to regenerative medicine. Nat. Rev. Cardiol. 7(12), 700-710 (2010).
29. Kohl P, Crampin EJ, Quinn TA, Noble D. Systems biology -an approach. Clin. Pharmacol. Ther. 88(1), 25-33 (2010).
30. Arrell DK, Terzic A. Network systems biology for drug discovery. Clin. Pharmacol. Ther. 88(1), 120-125 (2010).